

Glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH): Design, Isolation, Synthesis and preliminary anti-malarial activity against *Plasmodium falciparum* 3D7 strains.

Yemback Kenneth Pierre

University of Yaounde I: Universite de Yaounde I

Eyong Kenneth Oben (✉ eyongkk@yahoo.com)

University of Yaounde I: Universite de Yaounde I

Noella M. Efangé

University of Buea

Michael HK. Kamdem

University of Johannesburg - Doornfontein Campus

Derek T. Ndinteh

University of Johannesburg - Doornfontein Campus

Patricia O. Odumosu

University of Jos

Gabriel N. Folefoc

University of Yaounde I: Universite de Yaounde I

Lawrence Ayong

Centre Pasteur du Cameroun

Thomas Werner

University of Paderborn: Universitat Paderborn

Research Article

Keywords: PfGAPDH, molecular docking, antimalarial drugs, lupane derivatives, *Baillonella toxisperma*

Posted Date: June 2nd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1601480/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH) for *Plasmodium falciparum* is a key glycolytic enzyme that catalyzes the conversion of glyceraldehyde 3-phosphate (G3P) into 1,3-bisphosphate glycerate (1,3-BPG), with the concomitant reduction of nicotinamide adenine dinucleotide (NAD⁺) to NADH. Compounds from the Cameroon Natural Product Library (CANAPL), were screened by molecular docking studies against the enzyme target PfGAPDH. Amongst these docking hits were the lupeol cinnamate (1) and oleanane cinnamate (2) with binding energies (E_b) of -10.55 kcal/mol and -10.51 kcal/mol respectively, compared to PfGAPDH inhibitors; heptelidic acid (-6.47 kcal/mol), iodoacetate (-3.98 kcal/mol) and pentalenolactone (-6.87 kcal/mol). To validate the docking results, triterpenoids with structural similarities to (1) and (2) were isolated from *Baillonella toxisperma* (Pierre); olean-12-en-3 β -hexadecanoate (3), 3- β -trans cinnamoyloxylup-20(29)-ene (4), oleanoic acid benzoate (5), 3 β -amyrin (6), taraxerol (7), betulonic acid (8), β -sitosterol (9), betulonic acid (10), 3 β -(trans-p-Coumaroyl)oxylup-20(29)-en-28-oic acid (11), and screened alongside Betuline (12) and oleanolic acid (13).

The favorable compounds 8 and 11 with 100% growth inhibition on *Plasmodium falciparum* 3D7 strains together with compounds 4, 10 and 12 were structurally optimized to afford new lupane derivatives with the privilege α - β unsaturated carbonyl medicinal scaffolds; - betulonic acid acryl aldehyde (14), betulin acryl aldehyde (15), 3 β -(trans-p-Coumaroyl)oxylup-20(29)-en-28-oic acid acryl aldehyde (16), 30-hydroxy betulonic acid (17), betulonic acid acryl aldehyde (18) and 3- β -trans cinnamoyloxylup-20(29)-ene acryl aldehyde (19) exhibiting more potent anti-malarial activities. Their assays afforded IC₅₀ values of 0.703 μ M, 2.15 μ M, 1.28 μ M, and 3.79 μ M for compounds 14, 15, 16 and 18 respectively.

These results validate our docking scores and indicate that the modified compounds with the privilege α , β - unsaturated carbonyl medicinal scaffolds could be further optimized into potent antimalarial agents.

Introduction

Global mapping data indicate that malaria continues to be a major challenge with about 3.3 billion people at risk of exposure (Kehr et al. 2010; Guerra et al. 2006). The 2021 WHO report reveals that about 241 million people are infected with about 627 000 deaths (Forlemu et al. 2017). The eradication of malaria through the development of new insecticides, mosquito vector disruptions through more hygienic environment and the development of new antimalarial therapeutic agents remain a major priority worldwide (Bloland 2014). Despite the existence of effective antimalarial drugs such as artemisinin and chloroquine, increasing parasite resistance to these drugs is a major reason for the continuous search of cost-effective and new analogues with novel modes of action (Plowe et al. 2007; Bray et al. 2003).

Malaria is a disease caused by parasites of the genus *Plasmodium*, with *P. falciparum* being the most pathogenic and attacks red blood cells. The absence of a durable Krebs cycle in these parasites and the sole dependence on glycolysis for energy needs makes glycolytic pathway enzymes potential targets for antimalarial chemotherapies (Verlinde et al. 2001; Kim and Dang 2005). Glyceraldehyde 3-phosphate


dehydrogenase (abbreviated as *Pf*GAPDH for *Plasmodium falciparum*) is a key glycolytic enzyme that catalyzes the conversion of Glyceraldehyde 3-phosphate (G3P) into 1,3-bisphosphate glycerate (1,3-BPG), with the concomitant reduction of nicotinamide adenine dinucleotide (NAD⁺) to NADH (Seidler 2013). This is the 6th step in the glycolytic breakdown of glucose, an important pathway of energy and carbon molecule supply which takes place in the cytosol of eukaryotic cells (Ismail and Park 2005).

In this study, a series of lupane derivatives were designed, isolated, synthesized and evaluated for antiplasmodial activity against *Plasmodium falciparum*.

Results And Discussion

2.1 *In-silico* docking results

The molecular docking analysis can provide an important view into ligand-enzyme bindings and conformations (Raeisi 2013). In order to explore the potential inhibitors of the *Pf*GAPDH, a molecular docking analysis was performed on a current collection of 4000 compounds from CANAPL (CAmeroonian NATural Products Library); a database of compounds isolated from Cameroonian medicinal plants from the Department of Organic Chemistry of the University of Yaounde 1. These compounds were docked into the active site of *Pf*GAPDH (PDB code: 1ywg). The best results are represented in Table 1 and show that the lupane 1 and oleanane 2 derivatives were the most promising and exhibited binding energy (-10.55 and - 10.51 kcal/mol) compared to *Pf*GAPDH inhibitors; heptelidic acid (-6.47 kcal/mol), iodoacetate (-3.98 kcal/mol) and pentalenolactone (-6.87 kcal/mol). In order to validate the docking results, compounds with structural similarities to lupane derivative 1, and 2 were isolated from *Baillonella toxisperma* (Pierre), modified and evaluated against *Plasmodium falciparum* 3D7 strains.



Class	subclass	compound	Estimated $\Delta G_{\text{Binding}}$ (kcal/mol)	Hydrogen bonding	
				Interacted ligand functional group	Interacted amino acid
Triterpene	Lupane	3 β -caffeoyloxy-lup-20(29)-en-6 α -ol (1)	-10.55	OH	Gly241, Asn319
	Oleanane	3 β -O-(E)-3,5-dihydroxycinnamoyl-olean-12-en-11-one (2)	-10.51	OH	Ser213
Standards drugs		Heptelidic acid	-6.47	O-	Gly215, Arg237, Asn185
		Iodoacetate	-3.98	O-	Arg237, Asn185
		Pentalenolactone	-6.87	O-	Cys153, Arg237, Asn185

Chemistry

3.1 Extraction, isolation and characterization

Plant material

The stem bark and leaves of *Baillonella toxisperma* was harvested in Bôt-Makak, in the Centre Region of Cameroon in May 2021 and authentication done at the National Herbarium in Yaounde, Cameroon by Mr Nana Victor (Botanist at National Herbarium in Yaounde, Cameroon) where a voucher specimen (14592 SRF/Cam) has been deposited.

Extraction and isolation of triterpenoids

7 kg of *Baillonella toxisperma* stem bark was air-dried, powdered and extracted using a sonicator at room temperature in methylene chloride-methanol (5 x 5 L) for 3 days. Filtration and concentration in a rotary evaporator afforded an oily reddish-brown extract (330 g). The crude extract (300 g) was fixed on silica gel (300 g) and subjected to flash chromatography on silica gel (200 g) eluting with *n*-hexane, Hex/CH₂Cl₂ (1:1), CH₂Cl₂/AcOEt (1:1), CH₂Cl₂/MeOH (1:1) and MeOH respectively to provide five main fractions. Fraction 1 (15 g, obtained with pure hexane) was subjected to further separation by column chromatography on silica gel (75 g), with a step-wise gradient of gradients of EtOAc in hexane as mobile phase, to yield 25 mg of olean-12-en-3 β -hexadecanoate (3) (Chaudhuri and Chawla 1987) and 40 mg of 3- β -trans cinnamoyloxylup-20(29)-ene (4) (Anjaneyulu and Ravi 1989) after recrystallisation in Hexane. Fraction 2 (14.8 g obtained with Hex/CH₂Cl₂ [1:1]) was fixed and chromatographed on a silica gel column eluted with increasing polarities of EtOAc and hexane to yield 5 mg of compound 3- β -trans

cinnamoyloxylup-20(29)-ene (4) and 5 mg of oleanoic acid benzoate (5). Fraction 3 (55 g obtained with $\text{CH}_2\text{Cl}_2/\text{AcOEt}$ [1:1]) was subjected to silica gel column chromatography and eluted with increasing polarities of EtOAc and hexane to yield 5 mg of 3 β -amyirin (6) (Bahuguna and Jangwan 1987), 6 mg of taraxerol (7) (Ogihara and al. 1987), 25 mg of betulonic acid (8) (Patra et al. 1988), 50 mg of β -sitosterol (9) (Chaturvedula and Prakash 2012), 50 mg of betulinic acid (10) (Mbah et al. 2011), 25 mg of 3 β -(*trans*-*p*-Coumaroyl)oxylup-20(29)-en-28-oic acid (11) (Mbah et al. 2011). Fraction 4 (12.9 g obtained with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ [1:1]) was fixed and chromatographed on a silica gel column eluted with varying proportions of EtOAc and hexane to yield 25 mg of compound 10 and 5 mg of compound 11 (Fig. 1).

Betuline (12) (Patra et al. 1988) with similar lupane scaffold and oleanolic acid (13) (Shao et al. 1989) previously isolated in our laboratory from *Alstonia scholaris* were also evaluated for structure activity relation (SAR) studies (Fig. 1).

2.2 Chemical transformations

To discover derivatives with structure-diversities, we introduced the privilege medicinal structure with α - β unsaturated carbonyl functions to our lupane scaffold, which led to the discovery of new lupane derivatives that possesses favorable anti-malarial efficacies against *P. falciparum* 3D7 strains.

The derivatives 14–19 were all obtained as white solids from silica gel column chromatographic purification by gradient elution using hexane/ethyl acetate. Their molecular formula were determined by LC-MS (APCI⁺).

Their ¹H NMR spectrum (500 MHz, CDCl_3 or DMSO-d_6) exhibited signals indicative of aldehyde protons at $\delta_{\text{H}} = 9.50$ (1H, s) and two terminal olefin protons at $\delta_{\text{H}} = 5.95$ (1H, d) and $\delta_{\text{H}} = 6.30$ (1H, d) and the disappearance of methyl-30 at $\delta_{\text{H}} = 1.59$ (3H, s).

Their ¹³C NMR spectrum (125 MHz, CDCl_3 or DMSO-d_6) exhibited signals for a carbonyl atom at $\delta_{\text{C}} = 196.0$ (CHO) and the disappearance of methyl carbon at $\delta_{\text{C}} = 18.2$ (CH_3 -30).

However, the appearance of α , β -unsaturated olefin peaks were not observed on the ¹³C NMR spectrum. The presence of these peaks at $\delta_{\text{C}} = 134.6$ and $\delta_{\text{C}} = 156.8$ were made evidence thanks to their HSQC and HMBC spectra.

The disappearance of these peaks during ¹³C NMR measurements maybe due to the inability of these bonds come into resonance due to the anisotropic effect of the carbonyl function.

The structures of the synthesized compounds were confirmed from the interpretation of their 1D and 2D NMR spectral data (Table 3).

Biological Activity

The isolated compounds and the new lupane derivatives **14**, **15**, **16**, **17**, **18** and **19** were evaluated against *P. falciparum*. Their percent growth inhibitions at 10 μM and half maximal inhibitory concentrations are reported in Table 3. The results indicated that the SeO_2 derivatives were more potent than their initial derivatives with compound **14** being the most active with an IC_{50} of 0.703 μM .

Table 4: Antiplasmodial activity results with more active compounds in red

Compounds	% growth inhibition	IC_{50} <i>Pf</i> 3D7 (μM)
3	11.92	NA
4	7.99	NA
5	NA	NA
6	0.00	NA
7	19.39	NA
8	100.00	3.88
9	53.50	NA
10	40.14	NA
11	100.00	1.38
12	0.00	NA
13	14.47	NA
14	99.45	0.703
15	98.38	2.15
16	100	1.28
17	79.8	10
18	98.28	3.79
19	15.4	NA
ART	NA	12.9

NA= not active

Conclusion

In summary, to develop potent anti-malaria agents based on lupane skeleton with better metabolic stabilities, we have designed, isolated, synthesized a series of lupane derivatives and evaluated their anti-malaria efficacies against *Plasmodium falciparum* 3D7 strains. The carbonyl group or 4-hydroxy cinamate group at position 3 of the lupane structure may greatly have an influence in the biological activities. The derived compounds with α - β unsaturated carbonyl motive show favorable antiplasmodial activities. In particular, compound **8** with % growth inhibition and IC_{50} values of 100 and 3.88 μM when transformed to compound **14** showed % growth inhibition and IC_{50} values of 100 and 0.703 μM respectively. Compound **11** also with % growth inhibition and IC_{50} values of 100 and 1.38 μM when transformed to compound **16** showed % growth inhibition and IC_{50} values of 100 and 1.28 μM respectively. Smaller concentrations of the derived compounds with α - β unsaturated carbonyl motive are

needed to produce 100 % growth inhibition. These compounds will further be studied for subsequent mode of action study.

Experimental

General experimental procedures

Melting points were performed on a Büchi SMP-20 melting point apparatus. The NMR spectra in chloroform-d and methanol-d₄ were obtained using Bruker BioSpin GmbH instruments, operating at 400 MHz for ¹H NMR and 100 MHz for ¹³C NMR. Chemical shifts are given in δ (ppm) using tetramethylsilane (TMS) as internal standard. EI-MS was obtained with JEOL JMS-600H mass spectrometer. The extraction of the plant material was done using a digital ultrasonic cleaner LMUC series of mark LABMAN (serial number L1328). Flash chromatography was performed on SCHOTT Buchner (Duran, West Germany) with a porosity of 4. Analytical thin-layer chromatography (TLC) was performed on precoated silica gel plates (Merck 60F₂₅₄; 20x20, 0.25 mm). Column chromatography was performed on silica gel (70-230 mesh; Merck). Chromatograms were visualized by spraying with a solution of 10 % H₂SO₄, iodine vapor or under ultraviolet light of wavelengths 254 and 366 nm.

Molecular docking studies

Preparation of Ligand

4000 compounds were selected from the CANAPL database and distributed in 39 classes namely Alkane, Alcohol, Alkaloid, Amide, Anthranol, Enthone, Aromatic compounds, Benzophenone, Carotenoids, Ceramide, Cerebroside, Chromone, Coumarin, Cyanogenic glycoside, Cyclitol (polyol), Depsidone, Endiandric acid, Fatty acid, Flavonoid, Ionone, Iridoid, Labdane, Lactone, Lignane, Limonoid, Monoterpene, Peptide cyclic, Pterocarpans, Pyrone, Quinone, Sesquiterpene lactone, Saponins, Sesquiterpenoid, Sphingolipid, Steroid, Stilbenes, Sugar, Tannin, Terpenoids and Xanthone. The 3D structures of the phytoconstituents were retrieved from our chemical database and saved in .pdb format using Chem3D 15.0. The ligands were imported to the workspace and preparation was done for docking studies. The docking results of different constituents were compared against the reference drugs (heptelidic acid, iodoacetate and pentalenolactone) (Cane and Sohng 1989; Karja et al. 2009) obtained from the drug bank in chemdraw (*.cdx) format.

Preparation of Enzyme

The target for docking studies selected was Glyceraldehyde 3-phosphate dehydrogenase. Docking analysis was done by initially selecting the target for the disease and followed by obtaining the 3D structure of Glyceraldehyde 3-phosphate dehydrogenase (1ywg) (Satchell et al. 2005) from protein data bank (<http://www.rcsb.org>) in .pdb format.

The AutoDockTools (Morris et al. 2009) (ADT) was used to prepare the ligand and receptor structures, add appropriate Gasteiger and Kollman charges, identify and modify ligand rotatable bonds (Sanner 1999). The potential binding sites of target were calculated using the Lamarckian GA (4.2) algorithm implemented in Autodock4 (Morris et al. 1998). The population size, maximum number of evaluation (medium) and maximum number of generations were set at 150, 27 000 and 2 500 000 respectively (Bahadoria et al. 2016). The search space of the simulation exploited in the docking studies was studied as a subset region of 0.375Å around the active site (Robien et al. 2006). The water molecules were removed from the enzyme to decrease interactions between functional group of ligands and water molecules.

Parameters for docking functions

At this time, more than 30 molecular docking programs are available (Missier et al. 2010). The commonly used are AutoDock (Dhanick et al. 2012), GOLD, FlexX, DOCK and ICM. According to Sousa et al., (Sousa et al. 2006) we performed *in-silico* docking analysis by using Autodock4.0 (Lindstrom et al. 2008). This software uses two programs:

AutoGrid program calculates the interactions cards of grid in order to maximize evaluation step of different configurations of ligands. A grid surrounds the receptor protein and the ligand is placed at each intersection. The energy of interaction of this molecule with the protein is calculated and assigned to the location of the probe atom on the grid. An affinity grid is calculated for each type of ligand atom. The energy calculation time using the grids is proportional to the number of atoms of the ligand but it's independent of the number of atoms in the enzyme.

AutoDock program performs the research and evaluation of the different ligand configurations. It is possible to use several techniques to obtain the configurations (by simulated annealing, genetic algorithm or by Lamarckian genetic algorithm).

A grid-based method was used to enhance the quick evaluation of the binding energy of conformations of the complexes formed. The grid boxes were centered using coordinates of a virtual center of mass atom for the enzymes (Forlemu et al. 2017). A grid box had dimensions of 44 Å × 44 Å × 58 Å respectively in x, y and z dimension according to amino acids which formed active site (Cys153 - His180). The affinity of the docked complexes was described using dissociation constants (K_d) (Equation (1)), binding energy based on the semi empirical force field expression as described in Equation (2) (Huey et al. 2006) and H-Bond interactions.

$$K_i = \text{Exp}(-\Delta G/RT) \quad (1)$$

Where K_i (dissociation constant, and i indicates it is also an inhibition constant)

$$\Delta G_{bind} = \Delta G_{vdw} + \Delta G_{hbond} + \Delta G_{elect} + \Delta G_{tor} + \Delta G_{desolva} \quad (2)$$

ΔG_{bind}	Free Energy of Binding
ΔG_{vdw}	Van der Waals potential
ΔG_{hbond}	Hydrogen bonding potential
ΔG_{elect}	Electrostatic Potential
ΔG_{tor}	Torsional energy
$\Delta G_{desolva}$	Free Energy of desolvation

Synthesis

Procedure for the oxidation of some triterpenoids with selenium oxide SeO_2

To a dry DCM or Dioxane solution of the olefin in a 100 mL conical flask, SeO_2 was added (1.5 eq) at room temperature. The reaction mixture was refluxed while stirring for 1-3 h. After partial evaporation of the solvent to reduce the volume of the mixture, the residue was fixed to silica gel and submitted to column chromatography using Hex/AcOEt in various proportions.

Betulonic acid acrylaldehyde 14: white solid (CH_2Cl_2); (Hex/AcOEt 18%); mp 182 °C; ^1H NMR (CDCl_3 , 500 MHz): $\delta = 9.50$ (1H, s, H-30), $\delta = 6.30$ and 5.94 (each 1H, br s, H-29), 1.27 and 1.09 (each 3H, 2X CH_3), 1.01-0.99 (6H, s), 0.95 (3H, s, CH_3); ^{13}C NMR (CDCl_3 , 125 MHz): $\delta = 218.1$ (C, C-3), $\delta = 198.2$ (C, C-30), 180.9 (C, C-28), 147.3 (C, C-20), 105.8 (CH_2 , C-29).

Betuline acrylaldehyde 15: white solid ($\text{CH}_2\text{Cl}_2/\text{MeOH}$); (Hex/AcOEt 27%); mp 258 °C; ^1H NMR (CDCl_3 , 500 MHz): $\delta = 9.51$ (1H, s, H-30), $\delta = 6.31$ and 5.93 (each 1H, br s, H-29), 1.27 and 1.09 (each 3H, 2X CH_3), 1.01-0.99 (6H, s), 0.95 (3H, s, CH_3); ^{13}C NMR (CDCl_3 , 125 MHz): $\delta = 198.4$ (C, C-30), 180.9 (C, C-28), 148.3 (C, C-20), 105.8 (CH_2 , C-29), $\delta = 79.01$ (C, C-3).

3 β -(trans-p-Coumaroyl)oxylup-20(29)-en-28-oic acid acrylaldehyde 16: white solid ($\text{CH}_2\text{Cl}_2/\text{MeOH}$); (Hex/AcOEt 28.5%); mp 300 °C; ^1H NMR (CDCl_3 , 500 MHz): $\delta = 9.53$ (1H, s, H-30), $\delta = 7.48$ (1H, d, J = 15.0 Hz, H-3'), 7.31 (2H, d, J = 5.0 Hz, H-3'', H5''), 6.72 (2H, d, J = 5.0 Hz, H-2'', H-6''), 6.15 (1H, d, J = 15.0 Hz, H-2'), 6.47 and 6.10 (each 1H, br s, H-29), 4.43 (1H, m, H-3a), 0.98, 0.94, 0.90, 0.88 and 0.87 (each 3H, s, H-23, H-24, H-25, H-26 and H-27 respectively).

30-hydroxy betulonic acid 17: white solid ($\text{CH}_2\text{Cl}_2/\text{MeOH}$); (Hex/AcOEt 21%); mp 250 °C; ^1H NMR (CDCl_3 , 500 MHz): $\delta = 4.14$ (1H, dd, H-3), 3.20-2.80 (2H, dd, H-30), 0.88 (3H, d, J = 10Hz, H-29), 0.87, 0.86 and 0.85 (each 3H, s, 3x CH_3), 0.73 (3H, s, CH_3), 0.65 (3H, s, CH_3); ^{13}C NMR (CDCl_3 , 125 MHz): $\delta = 179.1$ (C, C-28), 78.8 (CH, C-3), 60.4 (CH_2 , C-30).

Betulinic acid acrylaldehyde 18: white solid (CH₂Cl₂/MeOH); (Hex/AcOEt 23%); mp 284 °C; ¹H NMR (CDCl₃, 500 MHz): δ = 9.55 (1H, s, H-30), δ = 6.31 and 5.94 (each 1H, br s, H-29), 3.20 (1H, m, H-3), 1.27 and 1.09 (each 3H, 2XCH₃), 1.01-0.99 (6H, s), 0.95 (3H, s, CH₃); ¹³C NMR (CDCl₃, 125 MHz): δ = 194.9 (C, C-30), 180.9 (C, C-28), 147.3 (C, C-20), 105.8 (CH₂, C-29), δ = 78.9 (C, C-3).

(3β-trans cinnamoyloxylup-20(29)-ene) acrylaldehyde 19: white solid (CH₂Cl₂/MeOH); (Hex/AcOEt 6%); mp °C; ¹H NMR (CDCl₃, 500 MHz): δ = 9.54 (1H, s, H-30), δ = 7.68 (1H, d, J = 15.0 Hz, H-3'), 7.54-7.40 (5H, m, H-2'', H-3'', H-4'', H-5'', H-6''), 6.46 (1H, d, J = 15.0 Hz, H-2'), 6.32-5.95 (each 1H, br s, H-29), 4.63 (1H, m, H-3a), 0.96, 1.05, 0.91, 0.89, 0.85, 0.94 (each 3H, s, H-23, H-24, H-25, H-26, H-27 and H-28 respectively).

Biological activity

Plasmodium falciparum culture and growth inhibition assay

Plasmodium falciparum 3D7 (chloroquine-sensitive) strain was obtained from the Biodefense and Emerging Infections (BEI) Research Resources (Manassas, VA) and maintained using a modified Trager and Jensen method. Briefly, parasites were cultured in fresh O+ human red blood cells at 3% (v/v) hematocrit in RPMI 1640 culture media containing glutamax and NaHCO₃ (Gibco, UK), supplemented with 25 mM HEPES (Gibco, UK), 1X hypoxanthine (Gibco, USA), 20 µg/mL gentamicin (Gibco, China), and 0.5% Albumax II (Gibco, USA). When needed, parasites were synchronized at the ring stage by sorbitol treatment and cultured through one cycle before treatment.

Stock compound solutions were diluted in incomplete RPMI 1640 and mixed with parasite cultures (1% parasitemia and 1.5% hematocrit) in 96-well plates to a final drug concentration of 10 µM for hit identification studies, or 10 – 0.078 µM for activity confirmation assays. The final dimethyl sulfoxide (DMSO) concentration per 100 µL culture per well was 0.1%. Artemisinin at 1 µM was used as negative growth control, while the solvent treated culture (0.1% DMSO) was used as positive growth control. Following 72 h incubation at 37 °C, parasite growth was assessed by a SYBR green I-based DNA quantification assay. In brief, a 3X concentrated SYBR Green lysis buffer was added to each plate well containing parasitized erythrocytes and kept in the dark for about 30 minutes. Fluorescence was measured using a Fluoroskan Ascent multi-well plate reader with excitation and emission wavelengths at 485 and 538 nm, respectively. Mean half-maximal inhibitory concentrations (IC₅₀ values) were derived by plotting percent growth against log drug concentration and fitting the response data to a variable slope sigmoidal curve function using GraphPad Prism v8.0.

Declarations

ACKNOWLEDGEMENTS

The authors thank the Faculty of Science of the University of Yaounde I, Malaria Research Unit "Centre Pasteur du Cameroun" and Drug Discovery and Smart Molecules Research Laboratory, Department of

Chemical Sciences, University of Johannesburg for providing us with all the facilities for the successful completion of the project.

Financial support and sponsorship: University of Yaounde I and Malaria Research Unit “Centre Pasteur du Cameroun”.

Conflict of Interests: There are no conflicts of interest.

References

1. Anjaneyulu V, Ravi K (1989) Triterpenoids from *Mangifera indica*. *Phytochem* 28:1695
2. Bahadoria MB, Dinparast L, Valizadeh H, Farimani MM, Ebrahimi SN (2016) Bioactive constituents from roots of *Salvia syriaca* L.: Acetylcholinesterase inhibitory activity and molecular docking studies. *South Afr J of Bot* 106:1–4
3. Bahuguna RP, Jangwan JS (1987) Puddumin-A, a new flavanone glucoside from *Prunus cerasoides*. *J Nat Prod* 50:309
4. Bloland BP (2014) Drug Resistance in Malaria, WHO Report. World Health Organization, Chamblee
5. Bray PG, Barrett PM, Ward AS, De Koning PD (2003) Pentamidine Uptake and Resistance in Pathogenic Protozoa: Past, Present and Future. *Trends Parasit* 19:232–239
6. Cane DE, Sohng J-K (1989) Inhibition of Glyceraldehyde-3-phosphate Dehydrogenase by Pentalenolactone: Kinetic and Mechanistic Studies. *Arch Biochem Biophys* 270:50–61
7. Chaturvedula VSP, Prakash I (2012) Isolation of stigmasterol and β -sitosterol from the dichloromethane extract of *Rubus suavissimus*. *Int Cur Pharm J* 1:239–242
8. Chaudhuri K, Chawla HM (1987) Anthraquinones and terpenoids from *Cassia javanica* leaves. *J Nat Prod* 50:1183
9. Dhanik A, SMcMurray J, Kavraki L (2012) AutoDock based incremental docking protocol to improve docking of large ligands. *IEEE Intern Conf Bioinform Biomed Workshops (BIBMW)* 48–55
10. Eyong KO, Chinthapally K, Senthilkumar S, Lamshoff M, Folefoc GN, Baskaran S (2015) Conversion of lapachol to lomatiol: synthesis of novel naphthoquinone derivatives. *New J Chem* 39:9611–9616
11. Forlemu N, Watkins P, Sloop J (2017) Molecular Docking of Selective Binding Affinity of Sulfonamide Derivatives as Potential Antimalarial Agents Targeting the Glycolytic Enzymes: GAPDH, Aldolase and TPI. *Open J Biophys* 7:41–57
12. Guerra CA, Snow RW, Hay SI (2006) Defining the Global Spatial Limits of Malaria Transmission in 2005. *Adv Parasit* 62:157–179
13. Gwandu UZ, Dangoggo SM, Faruk UZ, Halilu, Yusuf AJ, Mailafiya MM (2020) Isolation and Characterization of Oleanolic Acid Benzoate from the Ethylacetate Leaves Extracts of *Vernonia ambigua* (Kotschy Ex. Peyr). *J Chem Soc Nigeria* 45:1–6
14. Huey R, Morris GM, Olson AJ, Goodsell DSA (2006) Semi-Empirical Free Energy Force Field with Charge-Based Desolvation. *J Comput Chem* 28:1145–1152

15. Ismail SA, Park HW (2005) Crystal Structure of Human Liver GAPDH. *Acta Crystallogr D* 61:1508–1513
16. Karja NWK, Fahrudin M, Kikuchi K (2009) Inhibitory Effect of Iodoacetate on Developmental Competence of Porcine Early Stage Embryos *In Vitro*. *HAYATI J Biosc* 16:25–29
17. Kehr S, Stum N, Rahlfs S, Przyborski JM, Becker K (2010) Compartmentation of Redox Metabolism in Malaria Parasites. *PLoS Patho* 6:1–12
18. Kim JW, Dang CV (2005) Multifaceted Roles of Glycolytic Enzymes. *Trends Biochem Sci* 30:142–150
19. Lindstrom WM, Morris G, Weber C, Huey R (2008) Using AutoDock4 for virtual screening. *Scripps Res Inst Mol Graph Lab* 1:1–36
20. Missier P, Soiland-Reyes S, Owen S, Tan W, Nenadic A, Dunlop I, Williams A, Oinn T, Goble C (2010) Taverna, reloaded. *Int Conf Scien Stat Data Manag* 1:471–481
21. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. *J Comput Chem* 19:1639–1662
22. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J Comput Chem* 30:2785–2791
23. Ogihara K, Higa M, Hokama K, Suga T (1987) Triterpenes from the leaves of *Parsonia laevigata*. *Phytochem* 26:783
24. Patra A, Chaudhuri SK, Panda SK (1988) Betulin-3-caffeate from *Quercus suber*, ¹³C-nmr spectra of some lupenes. *J Nat Prod* 51:217
25. Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick RS, Mugittu K, Naidoo I, Price NR, Schafer WR, Sibley HC, Sutherland CJ, Zimmerman AP, Rosenthal JP (2007) World Antimalarial Resistance Network (WARN) III: Molecular Markers for Drug Resistant Malaria. *Malar J* 6:121–131
26. Raeisi S (2013) Molecular docking studies of squalene synthase inhibitors as potential anti cardiovascular disease drugs: insights into drug–protein interaction discovery *Pharm. Sci* 19:39–44
27. Robien MA, Bosch J, Buckner FS, Van Voorhis WC, Worthey EA, Myler P, Mehlin C, Boni EE, Kalyuzhniy O, Anderson L, Lauricella A, Gulde S, Luft JR, DeTitta G, Caruthers JM, Hodgson KO, Soltis M, Zucker F, Verlinde CL, Merritt EA, Schoenfeld LW, Hol WG (2006) Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from *Plasmodium falciparum* at 2.25 Å resolution reveals intriguing extra electron density in the active site. *Proteins* 62:570–577
28. Sanner MF (1999) Python: a programming language for software integration and development. *J Mol Graph Model* 17:57–61
29. Satchell JF, Malby RL, Luo CS, Adisa A, Alpyurek AE, Klonis N, Smith BJ, Tilley L, Colman PM (2005) Structure of glyceraldehyde-3-phosphate dehydrogenase from *Plasmodium falciparum*. *Acta Crystallogr Sect D: Biol Crystallogr* 61:1213–1221

30. Seidler NW (2013) GAPDH and intermediary metabolism. *Adv Experim Med Biol* 985:37–59
31. Shao CJ, Kasai R, Xu, JDa, Tanaka O (1989) Saponins from leaves of *Acanthopanax senticosus* Harms., ciwujia. II.: structures of ciwujianosides A1, A2, A3, A4 and D3. *Chem Pharm Bull* 37:42
32. Sousa SF, Fernandes PA, Ramos MJ (2006) Protein-Ligand Docking: Current Status and Future Challenges. *Proteins* 65:15–26
33. Verlinde CLMJ, Hannaert V, Blonski C, Willson M, Perie JJ, Fothergill-Gilmore LA, Opperdoes FR, Gelb MH, Hol WGJ, Michels PAM (2001) Glycolysis as a Target for the Design of New Anti-Trypanosome Drugs. *Drug Resist* 4:50–65

Tables 2-3

Tables 2-3 are available in the Supplementary Files section.

Figures




Figure 1

Structures of compounds isolated from *Baillonella toxisperma* (Pierre) including compounds 12 and 13

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SUPPORTINGINFORMATION24.04.22.docx](#)

- [Tables23.docx](#)